228 related articles for article (PubMed ID: 20920340)
1. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.
Wagener N; Macher-Goeppinger S; Pritsch M; Hüsing J; Hoppe-Seyler K; Schirmacher P; Pfitzenmaier J; Haferkamp A; Hoppe-Seyler F; Hohenfellner M
BMC Cancer; 2010 Oct; 10():524. PubMed ID: 20920340
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma.
Hatiboglu G; Pritsch M; Macher-Goeppinger S; Zöller M; Huber J; Haferkamp A; Pahernik S; Wagener N; Hohenfellner M
Scand J Urol; 2013 Aug; 47(4):311-22. PubMed ID: 23140095
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
PLoS One; 2013; 8(11):e81484. PubMed ID: 24312307
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
8. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
9. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].
Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722
[TBL] [Abstract][Full Text] [Related]
10. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
[TBL] [Abstract][Full Text] [Related]
11. Impact of E-Cadherin and β-Catenin as Prognostic Factor in Renal Cell Carcinoma with Tumor Thrombus of the Vena Cava.
Spachmann PJ; Breyer J; Kalogirou C; Lausenmeyer EM; Weber F; Prohaska S; Denzinger S; Burger M; Kübler H; Otto W; Vergho D
Urol Int; 2019; 102(4):413-420. PubMed ID: 30844790
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.
Mignogna C; Staibano S; Altieri V; De Rosa G; Pannone G; Santoro A; Zamparese R; D'Armiento M; Rocchetti R; Mezza E; Nasti M; Strazzullo V; Montanaro V; Mascolo M; Bufo P
BMC Cancer; 2006 Dec; 6():293. PubMed ID: 17177989
[TBL] [Abstract][Full Text] [Related]
13. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
15. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.
Singla N; Krabbe LM; Aydin AM; Panwar V; Woldu SL; Freifeld Y; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Bagrodia A; Kapur P; Margulis V
Urol Oncol; 2018 Jul; 36(7):343.e1-343.e8. PubMed ID: 29748098
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Eichelberg C; Minner S; Isbarn H; Burandt E; Terracciano L; Moch H; Kell A; Heuer R; Chun FK; Sauter G; Fisch M; Tennstedt P
World J Urol; 2013 Aug; 31(4):847-53. PubMed ID: 22009118
[TBL] [Abstract][Full Text] [Related]
17. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
[TBL] [Abstract][Full Text] [Related]
18. Proteomic identification of Reticulocalbin 1 as potential tumor marker in renal cell carcinoma.
Giribaldi G; Barbero G; Mandili G; Daniele L; Khadjavi A; Notarpietro A; Ulliers D; Prato M; Minero VG; Battaglia A; Allasia M; Bosio A; Sapino A; Gontero P; Frea B; Fontana D; Destefanis P
J Proteomics; 2013 Oct; 91():385-92. PubMed ID: 23916412
[TBL] [Abstract][Full Text] [Related]
19. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
Lee HW; Choe M
Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
[TBL] [Abstract][Full Text] [Related]
20. High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Eichenauer T; Simmendinger L; Fraune C; Mandelkow T; Blessin NC; Kluth M; Hube-Magg C; Möller K; Clauditz T; Weidemann S; Dahlem R; Fisch M; Riechardt S; Simon R; Sauter G; Büscheck F; Rink M
World J Urol; 2021 Feb; 39(2):481-490. PubMed ID: 32303902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
